A Phase 3 interventional study of pegfilgrastim in Neutropenia, sponsored by Amgen. Completed. Per ClinicalTrials.gov, last updated 2013-05-09.
Sponsored by Amgen · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing pegfilgrastim in Neutropenia — none open to participants now, none under way, none of them phase 3. pegfilgrastim · Neutropenia.
Among the 33 studies testing pegfilgrastim in Neutropenia, this one has the largest enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2002, is one of 11 in phase 3, and was the 3rd registered.
316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.
Browse Neutropenia studies →None of the 33 studies testing pegfilgrastim in Neutropenia is open now. The open studies under Neutropenia, anywhere →
pegfilgrastim: first FDA approval 2002 (NEULASTA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 5 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 928 is above the median of 82 across 230 interventional studies indexed under Neutropenia.
Median enrollment 121 across the 28 interventional studies. Of the 28 that completed or were terminated, 5 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
14 studies in Neutropenia by Amgen: none open now, none under way, none of them phase 3. Of 14 finished, 1 (7%) have results posted.
Among the 14 studies in Neutropenia by Amgen, this one is one of 5 that started in 2002, is one of 3 in phase 3, and was the 2nd registered.
Amgen’s Neutropenia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing pegfilgrastim in Neutropenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 14 in Neutropenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Physicians are conducting a clinical trial for patients with advanced breast cancer. Breast cancer can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced. Neutrophils are a type of white blood cells that fight infection and are produced in the bone marrow. If the neutrophil count becomes low due to chemotherapy, a potentially serious condition called neutropenia occurs. Neutropenia is serious because it can affect the body's ability to protect against many types of infections. Pegfilgrastim is an investigational drug being evaluated for its potential ability to increase the number of neutrophils. The purpose of this study is to determine the safety and effectiveness of pegfilgrastim in preventing neutropenia following chemotherapy in patients with advanced breast cancer.
Breast cancer patients receiving docetaxel chemotherapy and placebo.
Drug: pegfilgrastim
Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
Drug: pegfilgrastim
Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
Proportion of subjects developing febrile neutropenia
Time frame: Through 4 cycles
Incidence of hospitalization and IV antiinfective use associated with FN; also chemotherapy planned dose on time
Time frame: Through 4 cycles
No study locations are listed for this record.
The record gives a start of Feb 2002, a primary completion of Feb 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegfilgrastim